Announcement PDF ASX/Media Release 28/08/2020 Emerald Clinics successfully raises $2.2m in placement • • • • New funds will enable Emerald to continue expansion of its clinical services, R&D, business development and general working capital 27.5 million shares to be issued at $0.08 per share Strong demand for the placement attracts investment from new and existing institutional and sophisticated investors Continued momentum for Emerald after record month & major data deal secured Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a Real-World Evidence company that develops remote patient monitoring technology underpinned by a clinical services model, is pleased to announce that it has received binding commitments for a placement of new shares to raise $2.2 million. The placement of 27.5 million ordinary new shares in Emerald will be at $0.08 per share, a 13.1% discount to the five-day VWAP of $0.0921. The placement received strong demand from a combination of new and existing institutional and sophisticated investors in Australia and international markets. The funds raised in the placement will be used for expansion of clinical services, research and development, business development opportunities and general working capital. “We’re appreciative of the strong response to this capital raising as investors see the recent progress the business has made and its potential,” said Emerald Clinics CEO Dr Michael Winlo. “Coming off a record month in July and a major data deal in the UK, the injection of new capital will add to our momentum as we pursue various near-term commercial opportunities.” The new shares will be issued utilising the Company’s existing placement capacity under ASX Listing Rule 7.1. Shares under the Placement are expected to be issued on Monday, 7 September 2020 (subject to receipt of cleared funds). An Appendix 3B (Proposed issue of securities) have been released in relation to this announcement. Emerald has announced its intention to change its name to Emyria Limited, pending shareholder approval at a general meeting to be held on 18 September 2020. Release authorised by: Dr Michael Winlo, CEO and Managing Director For further information: Dr Michael Winlo CEO (08) 6559 2800 investors@emeraldclinics.com.au Matt Wright Media/investor relations +61 (0) 451 896 420 matt@nwrcommunications.com.au About Emerald Clinics Limited Emerald Clinics Limited (ACN 625 085 734) is an Australian incorporated company focussed on generating Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology. The Emerald model provides care while also co-creating high quality and ethically sourced clinical data from informed and consenting patients. Emerald’s evidence is used to accelerate the development of new treatments and models of care. Emerald customers pay for deidentified data, clinical trials and consulting services or monitor their workforce. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forwardlooking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.